Search results for "Obstructive"

showing 10 items of 609 documents

Twenty-year follow-up of children with obstructive sleep apnea.

2022

STUDY OBJECTIVES: Obstructive sleep apnea (OSA) in children is associated with acute metabolic, cardiovascular, and neurocognitive abnormalities. The long-term outcomes of childhood OSA into adulthood have not been established. We performed a 20-year follow-up of patients with polysomnography-documented OSA in childhood compared to a healthy control group to evaluate the long-term anthropometric, sleep, cognitive, and cardiovascular outcomes. METHODS: Children diagnosed with severe OSA between ages 1 and 17 years (mean, 4.87 ± 2.77) were prospectively contacted by telephone as young adults after approximately 20 years. Data collected included reported anthropometric information, educational…

Pulmonary and Respiratory MedicineCOVID-19 children obstructive sleep apnea sleep-disordered breathingAdultSleep Apnea ObstructiveAdolescentPolysomnographysleep-disordered breathingSnoringCOVID-19InfantScientific Investigationsnervous system diseasesrespiratory tract diseasesNeurologychildrenChild PreschoolHumansNeurology (clinical)Childobstructive sleep apneaFollow-Up StudiesJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
researchProduct

Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine

2014

Abstract The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a ìmultilevel cycleî responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of t…

Pulmonary and Respiratory MedicineChronic ObstructiveAntioxidantantioxidantNeutrophilsmedicine.medical_treatmentAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative Stress; Pulmonary and Respiratory MedicineAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative StressOxidative phosphorylationReviewSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAntioxidantsAcetylcysteinePulmonary Diseasechemistry.chemical_compoundPulmonary Disease Chronic ObstructiveCOPD exacerbationForced Expiratory VolumemedicineHumansRespiratory systemChronicBronchitisExpectorantschemistry.chemical_classificationCOPDReactive oxygen speciessmall airwaysbusiness.industryMacrophageslung functionGlutathionemedicine.diseaseAcetylcysteineBronchitis ChronicHospitalizationOxidative StresschemistryImmunologyDisease ProgressionRespiratory Physiological PhenomenabusinessReactive Oxygen SpeciesOxidative stressmedicine.drug
researchProduct

Chronic obstructive lung disease “expert system”: Validation of a predictive tool for assisting diagnosis

2018

Purpose: The purposes of this study were development and validation of an expert system (ES) aimed at supporting the diagnosis of chronic obstructive lung disease (COLD). Methods: A questionnaire and a WebFlex code were developed and validated in silico. An expert panel pilot validation on 60 cases and a clinical validation on 241 cases were performed. Results: The developed questionnaire and code validated in silico resulted in a suitable tool to support the medical diagnosis. The clinical validation of the ES was performed in an academic setting that included six different reference centers for respiratory diseases. The results of the ES expressed as a score associated with the risk of su…

Pulmonary and Respiratory MedicineChronic ObstructivePilot ProjectsExpert SystemsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary DiseasePulmonary Disease Chronic ObstructiveSoftware DesignSurveys and QuestionnairesChronic obstructive lung diseaseDiagnosisSurveys and QuestionnaireHumansAge FactorPilot ProjectExpert SystemChronic obstructive lung diseasesAgedHealth PolicyEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthMethodologyAge FactorsChronic obstructive lung diseases Diagnosis Expert systems Pulmonary and Respiratory Medicine Health Policy Public Health Environmental and Occupational HealthMiddle AgedAsthmaCoughSpirometrySample SizeChronic DiseasePublic HealthChronic obstructive lung diseases; Diagnosis; Expert systems; Age Factors; Aged; Asthma; Chronic Disease; Cough; Humans; Middle Aged; Pilot Projects; Pulmonary Disease Chronic Obstructive; Sample Size; Spirometry; Expert Systems; Software Design; Surveys and QuestionnairesDiagnosiHuman
researchProduct

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

2014

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real …

Pulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyAsthma; COPD; Randomized controlled trials; Real life studies; Asthma; Confounding Factors (Epidemiology); Humans; Pulmonary Disease Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Alternative medicineSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary DiseasePulmonary Disease Chronic ObstructiveRandomized controlled triallawIntervention (counseling)medicineCOPDHumansPharmacology (medical)Generalizability theoryMedical physicsInternal validityReal life studiesRandomized Controlled Trials as Topicbusiness.industryBiochemistry (medical)Gold standardConfounding Factors EpidemiologicVariance (accounting)Confounding Factors (Epidemiology)AsthmaReal life studieRandomized controlled trials; Real life studies; Asthma; COPDRandomized controlled trialResearch DesignRandomized controlled trialsPhysical therapybusinessStrengths and weaknesses
researchProduct

Phenotypes contribute to treatments.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region. Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment. 3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequ…

Pulmonary and Respiratory MedicineChronic bronchitismedicine.medical_specialtyExacerbation1InflammationDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineHumansCOPD030212 general & internal medicineCOPDbusiness.industryOriginal Articlesmedicine.diseasePhenotypeObstructive lung diseaserespiratory tract diseasesPhenotype030228 respiratory systemImmunologymedicine.symptomAirwaybusinessThe European respiratory journal
researchProduct

New modes in non-invasive ventilation

2016

IF 2.536; International audience; Non-invasive ventilation is useful to treat some forms of respiratory failure. Hence, the number of patients receiving this treatment is steadily increasing. Considerable conceptual and technical progress has been made in recent years by manufacturers concerning this technique. This includes new features committed to improve its effectiveness as well as patient-ventilator interactions. The goal of this review is to deal with latest advances in ventilatory modes and features available for non-invasive ventilation. We present a comprehensive analysis of new modes of ventilator assistance committed to treat respiratory failure (hybrid modes) and central and co…

Pulmonary and Respiratory MedicineComplex sleep apneamedicine.medical_specialtyCentral sleep apneaAdaptive servo ventilation[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/PediatricsCheyne-stokes respirationReview030204 cardiovascular system & hematologyPositive airway pressureRespiratory failure[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractAssured pressure support03 medical and health sciences0302 clinical medicinemedicineNeurally adjusted ventilatory assistVentilatory modesHumansIntensive care medicineObstructive pulmonary-diseaseComplex sleep-apnea[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsNoninvasive Ventilationbusiness.industryDiaphragm electrical-activityNon invasive ventilationmedicine.diseaseNeuro adjusted ventilatory assistClinical PracticeRandomized controlled-trialAdaptative servo ventilationChronic heart-failure030228 respiratory systemRespiratory failurePediatrics Perinatology and Child HealthBreathingCentral sleep apneabusinessRespiratory InsufficiencyImproves cardiac-function[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
researchProduct

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

2013

Background Guidelines for chronic obstructive pulmonary disease (COPD) recommend that treatment choices be based partly on symptoms. Methods A post-hoc analysis of pooled data from clinical studies compared the efficacy and safety of once-daily inhaled bronchodilators indacaterol (150 and 300 μg) and open-label tiotropium (18 μg) according to baseline dyspnoea severity on the modified Medical Research Council (mMRC) scale in patients with COPD (mMRC scores <2 = ‘less dyspnoea’; scores ≥2 = ‘more dyspnoea’). Outcomes were assessed after 26 weeks. Results The analysis included 3177 patients. In patients with less dyspnoea: indacaterol (both doses) improved 24-h post-dose (‘trough’) forced exp…

Pulmonary and Respiratory MedicineCopd patientsScopolamine DerivativesPulmonary diseaseQuinolonesPlaceboPulmonary Disease Chronic ObstructiveForced Expiratory VolumeMedicineHumansPharmacology (medical)In patientPooled dataTiotropium BromideRandomized Controlled Trials as TopicCOPDDose-Response Relationship Drugbusiness.industryBiochemistry (medical)Patient AcuityTreatment optionsmedicine.diseaserespiratory tract diseasesBronchodilator AgentsDyspneaAnesthesiaDelayed-Action PreparationsIndansIndacaterolbusinessmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.

2014

Abstract Background Epithelial to mesenchymal transition (EMT) is under discussion as a potential mechanism of small airway remodelling in COPD. In bronchial epithelium of COPD and smokers markers of EMT were described. In vitro, EMT may be reproduced by exposing well-differentiated human bronchial epithelial cells (WD-HBEC) to cigarette smoke extract (CSE). EMT may be mitigated by an increase in cellular cAMP. Objective This study explored the effects of roflumilast N-oxide, a PDE4 inhibitor on CSE-induced EMT in WD-HBEC and in primary bronchial epithelial cells from smokers and COPD in vitro. Methods WD-HBEC from normal donors were stimulated with CSE (2.5%) for 72 h in presence of roflum…

Pulmonary and Respiratory MedicineCyclopropanesMalePathologymedicine.medical_specialtyEpithelial-Mesenchymal TransitionAminopyridinesVimentinApoptosisBronchiEnzyme-Linked Immunosorbent AssayRespiratory MucosaIn Vitro TechniquesTransforming Growth Factor beta1Pulmonary Disease Chronic ObstructiveAnnexinSmokemedicineCyclic AMPHumansPharmacology (medical)Epithelial–mesenchymal transitiontabac efectes fisiològicsRoflumilastAgedchemistry.chemical_classificationReactive oxygen speciesbiologybusiness.industryBiochemistry (medical)Mesenchymal stem cellSmokingNOX4Epithelial CellsfarmacologiaMiddle Agedrespiratory tract diseaseschemistryApoptosisBenzamidesbiology.proteinCancer researchFemalePhosphodiesterase 4 Inhibitorspulmons malalties obstructivesbusinessReactive Oxygen Speciesmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct

Quantitative analysis of airway obstruction in lymphangioleiomyomatosis

2020

Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease with progressive pulmonary function loss caused by progressively proliferating LAM cells. The degree of airway obstruction has not been well investigated within the pathogenesis of LAM. Using a combination of ex vivo computed tomography (CT), microCT and histology, the site and nature of airway obstruction in LAM explant lungs was compared with matched control lungs (n=5 each). The total number of airways per generation, total airway counts, terminal bronchioles number and surface density were compared in LAM versus control. Ex vivo CT analysis demonstrated a reduced number of airways from generation 7 on (p<0.0001) in LAM compar…

Pulmonary and Respiratory MedicineLipopolysaccharidesPathologymedicine.medical_specialtyLung NeoplasmsPulmonary function testingPathogenesisOrphan Lung Diseases03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineMedicine and Health SciencesFLOW OBSTRUCTIONMedicineHumans030212 general & internal medicineLymphangioleiomyomatosisBronchiolesLungbusiness.industryHistologyOriginal ArticlesX-Ray MicrotomographyAirway obstructionrespiratory systemmedicine.disease133. Good healthrespiratory tract diseasesAirway Obstruction030228 respiratory systemPULMONARY LYMPHANGIOLEIOMYOMATOSISLymphangioleiomyomatosisHuman medicineAirwaybusinessQuantitative analysis (chemistry)Ex vivoCTThe European Respiratory Journal
researchProduct